Scarica l'app Stockscreener
24.44
3.13%
-0.79
Dopo l'orario di chiusura:
24.54
0.10
+0.41%
Precedente Chiudi:
$25.23
Aprire:
$25.48
Volume 24 ore:
1.04M
Relative Volume:
0.80
Capitalizzazione di mercato:
$3.11B
Reddito:
$236.00M
Utile/perdita netta:
$-369.00M
Rapporto P/E:
-7.6788
EPS:
-3.1828
Flusso di cassa netto:
$-489.00M
1 W Prestazione:
-2.12%
1M Prestazione:
-18.12%
6M Prestazione:
+6.45%
1 anno Prestazione:
+82.80%
Intervallo 1D:
$24.09
$25.58
Intervallo di 1 settimana:
$24.09
$26.35
Portata 52W:
$13.21
$31.73
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
24.44 | 3.18B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Wedbush Reiterates Arcus Biosciences At Outperform, Sets Price Target Of $43, Casdatifan Data Ahead - RTTNews
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo! Finance Canada
RCUS Reiterated by Wedbush -- Price Target Maintained at $43.00 - GuruFocus
Arcus Biosciences, Inc. (RCUS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Gilead Sciences Inc and Arcus Biosciences Inc Post ARC-7 Plenary Q&A Transcript - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance Singapore
Arcus Biosciences stock trades 16.8 percent below yearly high - AD HOC NEWS
(RCUS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
RCUS Looks 292.6% Overvalued on GF Value™ - GuruFocus
Cantor Fitzgerald reiterates Arcus Biosciences stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Arcus Biosciences stock rating - Investing.com
New kidney cancer data from 121 patients will be shared Oct. 20 - Stock Titan
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy - Yahoo Finance
Arcus Biosciences stock holds steady as investors eye latest clinical and earnings signals - AD HOC NEWS
Arcus Biosciences (RCUS) Stock Analysis: Exploring a 51.72% Potential Upside in Biotechnology - DirectorsTalk Interviews
Arcus Biosciences stock gains on TD Cowen buy rating - Investing.com
Arcus Biosciences stock gains on TD Cowen buy rating By Investing.com - Investing.com Canada
Why is Arcus Biosciences stock rallying today? By Investing.com - Investing.com UK
RCUS Initiates Coverage On by TD Cowen -- Rating Set to Buy - GuruFocus
Arcus Biosciences stock initiated at Buy by TD Cowen on RCC drug - Investing.com Australia
TD Cowen Initiates Arcus Biosciences at Buy - marketscreener.com
RCUS: Pivotal ARC-20 data and phase III trials aim to establish casdatifan as a market leader in RCC - TradingView
(RCUS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Arcus Biosciences Slides as Investors Weigh Pipeline Overhang Ahead of Next Data Catalysts - Quiver Quantitative
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Cooper Co (COO) and Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences at cantor global healthcare conference: casdatifan in focus By Investing.com - Investing.com Canada
Arcus Biosciences at cantor global healthcare conference: casdatifan in focus - Investing.com India
One new employee can buy 26,350 Arcus shares. Arcus also awarded rights to 13,200 shares. - Stock Titan
Arcus Biosciences at Citi summit: casdatifan data loom large By Investing.com - Investing.com India
Following VIRO 2025 Success, Arcus Biosciences Continues Partnership in 2026 - oncodaily.com
Truist raises Arcus Biosciences stock price target on trial data By Investing.com - Investing.com South Africa
RCUS Reiterated by Truist Securities -- Price Target Raised to $40 - GuruFocus
RCUS Q2 2026 Earnings: Narrower Loss Beats Estimates by 21.41%Quarterly Financial Update - dars.gov.et
Understanding the Setup: (RCUS) and Scalable Risk - Stock Traders Daily
Arcus Biosciences Inc. (RCUS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arcus Biosciences Inc. (RCUS) Peer Comparison – Compare with Others - Value Research
Arcus Biosciences Inc. (RCUS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Arcus Biosciences Inc. (RCUS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Arcus Biosciences (RCUS) Q1 2025 Earnings: Results, Market Reaction & History - 247wallst.com
Arcus Biosciences will take part in 3 New York conferences in September - Stock Titan
Why Arcus Biosciences (RCUS) Is Getting Attention Today - Sahm
Arcus Biosciences (RCUS) Slides 3.7% as Biotech Sector Volatility PersistsUpthrust Pattern - careplusvn.com
Arcus Biosciences CAO Azoy sells $84,810 in stock By Investing.com - Investing.com Nigeria
Arcus Biosciences CAO Azoy sells $84,810 in stock - Investing.com India
Arcus Biosciences (NASDAQ: RCUS) CAO sells shares from option plan - stocktitan.net
Arcus (RCUS) Range: Rises 2.78% to $30.34 in the Latest Session; Level Watch: Price Remains Between $28.82 Support and $31.86 Resistance on the DayVWAP Bounce - vinanet.vn
Arcus Biosciences (RCUS) officer eyes sale after June plan trades - Stock Titan
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales - Sahm
Investigation launched into Arcus Biosciences o... - Pluang
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm - Morningstar
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):